A new BOD estimation method employing a double-mediator system by ferricyanide and menadione using the eukaryote Saccharomyces cerevisiae
H Nakamura, K Suzuki, H Ishikuro, S Kinoshita… - Talanta, 2007 - Elsevier
A new biochemical oxygen demand (BOD) sensing method employing a double-mediator (DM)
system coupled with ferricyanide and a lipophilic mediator, menadione and the …
system coupled with ferricyanide and a lipophilic mediator, menadione and the …
Advances in allogeneic cancer cell therapy and future perspectives on “off-the-shelf” T cell therapy using iPSC technology and gene editing
Y Furukawa, Y Hamano, S Shirane, S Kinoshita… - Cells, 2022 - mdpi.com
The concept of allogeneic cell therapy was first presented over 60 years ago with hematopoietic
stem cell transplantation. However, complications such as graft versus host disease (…
stem cell transplantation. However, complications such as graft versus host disease (…
Rejuvenated iPSC-derived GD2-directed CART cells harbor robust cytotoxicity against small cell lung cancer
S Kinoshita, M Ishii, J Ando, T Kimura… - Cancer Research …, 2024 - aacrjournals.org
This research introduces iPSC-derived rejuvenated GD2-CARTs (GD2-CARrejT) as a novel
approach to combat SCLC. Compared with conventional GD2-CARTs, GD2-CARrejTs with …
approach to combat SCLC. Compared with conventional GD2-CARTs, GD2-CARrejTs with …
Artificial intelligence-driven label-free detection of chronic myeloid leukemia cells using ghost cytometry
…, N Watanabe, Y Tsukune, T Inano, S Kinoshita… - Scientific Reports, 2025 - nature.com
Early diagnosis and treatment initiation of chronic myeloid leukemia (CML) are considered
to increase the rate of deep molecular response. However, the early diagnosis of CML is …
to increase the rate of deep molecular response. However, the early diagnosis of CML is …
[HTML][HTML] iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer
…, M Ishii, J Ando, K Ikeda, KJ Igarashi, S Kinoshita… - Cell Reports …, 2023 - cell.com
Functionally rejuvenated human papilloma virus-specific cytotoxic T lymphocytes (HPV-rejTs)
generated from induced pluripotent stem cells robustly suppress cervical cancer. However, …
generated from induced pluripotent stem cells robustly suppress cervical cancer. However, …
l-asparaginase monotherapy as an encouraging approach towards acute fulminant chronic active Epstein-Barr virus infection
…, J Ando, M Ishii, S Kinoshita… - British journal of …, 2024 - pubmed.ncbi.nlm.nih.gov
… 1 , Shintaro Kinoshita …
[HTML][HTML] Eleven cases of laryngeal edema after tisagenlecleucel infusion: a 3-year single center retrospective study of CD19-directed chimeric antigen receptor T-cell …
E Hosoya, J Ando, S Kinoshita, Y Furukawa… - …, 2024 - pmc.ncbi.nlm.nih.gov
… 1, 2 , Shintaro Kinoshita Shintaro Kinoshita … Find articles by Shintaro Kinoshita …
[HTML][HTML] Establishment of ganglioside GD2-expressing extranodal NK/T-cell lymphoma cell line with scRNA-seq analysis
…, K Tachibana, Y Furukawa, T Toyota, S Kinoshita… - Experimental …, 2024 - Elsevier
Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL), is characterized by
Epstein-Barr virus infection and poor prognosis. We established a novel cell line, ENKL-J1, from …
Epstein-Barr virus infection and poor prognosis. We established a novel cell line, ENKL-J1, from …
Effectiveness of carbon ion radiotherapy for bone and soft tissue sarcoma in older patients
H Kinoshita, T Yonemoto, S Yamada… - Anticancer Research, 2024 - ar.iiarjournals.org
Background/Aim: The aging population is expected to increase the occurrences of bone
sarcoma (BS) and soft tissue sarcoma (STS). Carbon ion radiotherapy (CIRT) is reported to be …
sarcoma (BS) and soft tissue sarcoma (STS). Carbon ion radiotherapy (CIRT) is reported to be …
Trigenic ADH5/ALDH2/ADGRV1 mutations in myelodysplasia with Usher syndrome
S Kinoshita, M Ando, J Ando, M Ishii, Y Furukawa… - Heliyon, 2021 - cell.com
Trio-next generation sequencing is useful to identify undiagnosed inherited diseases. We
have attended a patient with trigenic ADH5/ALDH2/ADGRV1 pathogenic variants, which …
have attended a patient with trigenic ADH5/ALDH2/ADGRV1 pathogenic variants, which …